Zoetis Inc. (ZTS) Shares Bought by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 30.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,836,794 shares of the company’s stock after buying an additional 429,263 shares during the period. UBS Asset Management Americas Inc. owned about 0.37% of Zoetis worth $95,532,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. NEXT Financial Group Inc increased its position in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA boosted its stake in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares during the period. Finally, Penserra Capital Management LLC boosted its stake in shares of Zoetis by 94.6% in the third quarter. Penserra Capital Management LLC now owns 2,720 shares of the company’s stock worth $140,000 after buying an additional 1,322 shares during the period. 92.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 50.15 on Tuesday. The stock has a market cap of $24.77 billion, a price-to-earnings ratio of 36.16 and a beta of 1.05. The stock’s 50 day moving average is $50.03 and its 200 day moving average is $49.67. Zoetis Inc. has a 52-week low of $38.26 and a 52-week high of $53.14.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.46 by $0.06. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.22 billion. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 earnings per share. On average, equities analysts predict that Zoetis Inc. will post $1.94 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be given a dividend of $0.095 per share. This represents a $0.38 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend is Tuesday, November 1st. Zoetis’s payout ratio is currently 27.54%.

ILLEGAL ACTIVITY WARNING: “Zoetis Inc. (ZTS) Shares Bought by UBS Asset Management Americas Inc.” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/zoetis-inc-zts-shares-bought-by-ubs-asset-management-americas-inc.html.

A number of analysts have recently commented on ZTS shares. Argus boosted their target price on shares of Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a report on Friday, September 9th. Jefferies Group restated a “buy” rating and set a $60.00 target price on shares of Zoetis in a report on Tuesday, August 23rd. Bank of America Corp. started coverage on shares of Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and set a $58.00 target price on shares of Zoetis in a report on Wednesday, October 12th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $56.00 target price on the stock in a report on Monday, November 7th. Two research analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus price target of $55.92.

In related news, Director Michael B. Mccallister acquired 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were bought at an average price of $51.34 per share, with a total value of $102,680.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Heidi C. Chen sold 32,097 shares of the firm’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $50.98, for a total value of $1,636,305.06. Following the completion of the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at approximately $2,348,138.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.